Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday.

Several other analysts have also weighed in on the company. Oppenheimer restated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, August 9th. Finally, Canaccord Genuity Group raised their target price on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Regulus Therapeutics has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Stock Up 1.3 %

Shares of NASDAQ:RGLS opened at $1.62 on Tuesday. The firm has a fifty day simple moving average of $1.64 and a two-hundred day simple moving average of $2.04. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79. The stock has a market capitalization of $106.06 million, a P/E ratio of -1.11 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). On average, analysts expect that Regulus Therapeutics will post -0.8 earnings per share for the current year.

Institutional Trading of Regulus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. grew its holdings in shares of Regulus Therapeutics by 16.5% in the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 38,529 shares during the last quarter. Renaissance Technologies LLC grew its stake in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Regulus Therapeutics during the second quarter worth approximately $136,000. Opaleye Management Inc. bought a new stake in shares of Regulus Therapeutics during the first quarter valued at approximately $490,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Regulus Therapeutics in the second quarter valued at approximately $352,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.